A phase Ib clinical trial evaluating HER-Vaxx (IMU - 131), a B-cell epitope vaccine targeting HER2, in patients with advanced HER2-positive GC reported promising outcomes (61). This evidence concerns the gene ERBB2 and gastric cancer.